AyurMaya Capital, a private equity firm, led a $401m Series D round in ElevateBio, a biotechnology company, with participation from Woodline, Novo Nordisk, Matrix Capital Management, The Invus Group, Emerson Collective, SoftBank Vision Fund 2, Fidelity Management & Research Company, MPM Capital, F2 Ventures, Redmile Group, EcoR1 Capital, Samsara BioCapital, Surveyor Capital, EDBI, Vertex Ventures and iTochu. “ElevateBio has created a truly disruptive business model with integrated technologies, capabilities, and capacity for which we see accelerating need as the complexity of cell and gene therapies continues to grow. In this still-nascent industry, we believe ElevateBio is looking several steps ahead to pave the path for partners across the biopharmaceutical industry to accelerate innovation and bridge the gap between discovery and widespread delivery of cell and gene therapies as everyday medicine,” Khalil Barrage, The Invus Group Managing Director.